basiliximab + mycophenolic acid + corticosteroids

A combination immunosuppressive regimen consisting of **basiliximab**, **mycophenolic acid**, and **corticosteroids** is primarily used to prevent organ transplant rejection, especially in kidney and liver transplantation. - **Basiliximab** is a chimeric monoclonal antibody that selectively binds to the CD25 (alpha chain) of the interleukin-2 receptor on activated T-lymphocytes, thereby blocking IL-2 mediated T-cell activation and proliferation, reducing the cellular immune response involved in transplant rejection[2][4][6]. - **Mycophenolic acid** is an inosine monophosphate dehydrogenase inhibitor that suppresses lymphocyte proliferation by inhibiting guanine nucleotide synthesis, primarily used as an immunosuppressive adjunct to prevent organ rejection[5]. - **Corticosteroids** act as broad-spectrum immunosuppressive agents that inhibit multiple inflammatory pathways, reduce cytokine production, and suppress immune cell activity. The combination targets different aspects of the immune response, providing an effective approach to minimizing acute rejection and preserving graft function in transplant patients[1][3][5][7]. This regimen is typically used as part of induction and maintenance immunosuppression, with basiliximab given perioperatively and mycophenolic acid plus corticosteroids administered orally or intravenously post-transplant[3][7].